Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Curtain Sign
NEJM 387:e7, Sherman, S.V., 2022
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Clinical Manifestations of Myasthenia Gravis
UptoDate Aug 2016, Bird, S.J., 2016
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
Does This Patient Have Myasthenia Gravis?
JAMA 293:1906-1914, Scherer,K.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Respiratory Management in Acute Neurologic Illness
Neurol 50:11-20, Wijdicks,E.F.M.&Borel,C.O., 1998
Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992
Neurological Problems in Endocrine Diseases
Med Clin North Am 56:1029, Dale,A., 1972